Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.
about
Small cell lung cancer (SCLC): no treatment advances in recent yearsNomogram prediction for the survival of the patients with small cell lung cancer.Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients.Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancerPredictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposideKnockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer.Lung cancer stigma, depression, and quality of life among ever and never smokersCancer Stem Cells in Small Cell Lung Cancer Cell Line H446: Higher Dependency on Oxidative Phosphorylation and Mitochondrial Substrate-Level Phosphorylation than Non-Stem Cancer CellsEffect of cigarette smoking on quality of life in small cell lung cancer patientsLung cancer stigma, anxiety, depression, and quality of life.Lung cancer: Biology and treatment options.Targeted therapies in small-cell lung cancer.Consolidation chemotherapy improves progression-free survival in stage III small-cell lung cancer following concurrent chemoradiotherapy: a retrospective study.Vasculogenic mimicry in small cell lung cancer.Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database.Cancer stem cells in lung cancer: Evidence and controversies.Update on new drugs in small cell lung cancer.Notch signaling in lung cancer.Novel strategies for the treatment of small-cell lung carcinoma.The role of radiation therapy in small cell lung cancer.Lung cancer stem cells and implications for future therapeutics.Microtubule-associated protein 1B: Novel paraneoplastic biomarker.Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004.Surgical treatment of early stage small cell lung cancer.Frequency of O⁶-methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer.Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center.Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis.Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy.Immune checkpoint inhibitors in small cell lung cancer.
P2860
Q26767020-2B07BB90-5397-416A-A5C2-212BB810A217Q33571276-BDD69468-1415-441E-B3BD-C2D67F10C04AQ33625372-7E1EFC48-EB5D-4C4A-A89D-3BCEB5EAC16DQ33817153-3681B04C-602A-402B-BA95-EE2800B8C381Q34994818-431B9CBB-8795-4605-9D9E-0CC3AB2F14D3Q35789345-F84E1515-CBBF-46FD-8A7B-7A8555C50E5AQ35989582-90EB83F8-C9AA-420E-8215-2438B0529EFCQ36014432-E3834905-A4AB-4371-B3DF-53BD816EC5C8Q36116072-E1F1F23C-C013-4EC7-AFA1-7D97EE7629C9Q36252711-0E6A2C56-8342-4F9F-87DC-E4DC463D306CQ36328370-87AC4C2D-A099-4EFA-B228-77B04081743DQ36897340-44B3EE7D-9028-45EF-9D1D-62A5295140E8Q37283557-97107ED0-2442-4896-8B9E-6A5452302790Q37408684-6322916D-B5D0-4A34-A6D3-A59C26088E07Q37515251-BC3BCEA7-8C58-4126-84C6-E12B31B8B949Q37709551-EAD14BD1-D3A0-40D2-B3C5-1AFF863D948AQ37851992-3CCE2FCC-EB79-4E48-A707-CCD43D7E40DBQ37866784-71C36A9E-2076-44B2-9EED-3F4C700CD716Q37892341-16E2CC85-6B95-4902-81CC-C7733A361BA3Q38102613-5F00DC12-358B-4A20-BA58-C7671985E37FQ38189297-65A5EB96-54BB-4F28-B25A-434D604C7883Q38376430-FD75EA60-3DD8-4E86-AFE3-298AEBB71D28Q39044577-0BC66AE7-020F-4201-B61D-ECBB31CEBB03Q39375125-6EE43290-4B16-48EF-99C5-6E22EB5611D4Q40174767-229BD204-B522-47D4-967F-83B6904D8360Q50882852-B1A76C95-F51F-4807-89CE-3E3B8351F6C6Q52932452-48109C96-71DF-4715-9880-8DB51A887596Q53085123-B4F0DF98-1594-4947-A5F3-CEF17E58AEC8Q53734311-90E089CA-DBF0-4B02-AF14-12F92D69DE31Q55023905-C0E03CDD-7493-4DE7-9060-B059103CC33CQ55260269-77BAF75A-AE0A-478A-88B5-612865DBD50E
P2860
Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Twenty-five years of clinical ...... ng carcinoma in North America.
@ast
Twenty-five years of clinical ...... ng carcinoma in North America.
@en
Twenty-five years of clinical ...... ng carcinoma in North America.
@nl
type
label
Twenty-five years of clinical ...... ng carcinoma in North America.
@ast
Twenty-five years of clinical ...... ng carcinoma in North America.
@en
Twenty-five years of clinical ...... ng carcinoma in North America.
@nl
prefLabel
Twenty-five years of clinical ...... ng carcinoma in North America.
@ast
Twenty-five years of clinical ...... ng carcinoma in North America.
@en
Twenty-five years of clinical ...... ng carcinoma in North America.
@nl
P2093
P2860
P356
P1433
P1476
Twenty-five years of clinical ...... ng carcinoma in North America.
@en
P2093
Bruce E Johnson
David H Johnson
Frances A Shepherd
Robert B Livingston
Scott Saxman
P2860
P304
P356
10.1002/CNCR.10841
P407
P577
2002-10-01T00:00:00Z